VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Lysteda
Preclinical
Small molecule
K
Kay I Waud MD PhD
1
Indications
2
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Heavy Menstrual Bleeding
Unknown status
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Heavy Menstrual Bleeding
Preclinical
Unknown status
Clinical
Trials by Indication
[1]
Female
1 trial
Effect of Oral TXA on Buttock Bruising Post CCH Injections in Adult Females
Completed
·
L
Luxurgery
·
Phase 4
·
NCT05309525
·
17 enrolled
Heavy Menstrual Bleeding
1 trial
Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding
Unknown status
·
K
Kay I Waud MD PhD
·
N/A
·
NCT01659008
·
100 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for Lysteda. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Lysteda compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Lysteda. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Kay I Waud MD PhD company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
K
Kay I Waud MD PhD
Related News